Folks turning to injectable GLP-1 therapies—a category of medication that mimics that hormone to regulate diabetes and promote weight reduction—now have one other option to take the remedy.
On Dec. 22, the U.S. Meals and Drug Administration (FDA) permitted Wegovy capsule from Novo Nordisk. The capsule will comprise 25 mg of semaglutide—the identical compound within the injectable model of Wegovy—to deal with obese or weight problems, both for individuals who use the tablets to begin a weight-loss program or for many who use them to keep up weight reduction. Folks prescribed the capsule will take one a day. (By comparability, individuals utilizing the pen variations of the remedy inject themselves as soon as every week.)
“I’m excited to launch the capsule as a result of I’ve acknowledged that so many individuals proper now are in want of weight reduction however are nonetheless not going ahead with [medications like Wegovy] as a result of there’s a taboo with injections,” Novo Nordisk’s CEO Mike Doustdar tells TIME. “They wish to swallow a capsule with out being judged if somebody sees them injecting [a medication]. We waited and waited to ensure that when the capsule comes out, it’s the fitting one and probably the most efficacious one.”
Within the research the corporate submitted to the FDA, individuals who took the each day Wegovy capsule misplaced about the identical quantity of weight—round 16.6% of their physique mass—as those that gave themselves weekly Wegovy injections for simply over a yr.
Learn Extra: How a Nobel-Profitable Researcher Reworked Most cancers Remedies With His Lifesaving Curiosity
A protected and efficient weight-loss capsule has been a holy grail for pharmaceutical firms. One of many principal challenges with growing one is that medicines usually have a tough time surviving harsh abdomen acids. The brand new capsule incorporates proprietary know-how used at Novo Nordisk to quickly alter the particular space of the abdomen the place the capsule lands and stop it from getting degraded by the digestive enzymes too shortly, says Andrea Traina, medical director at Novo Nordisk. “That ends in a bioavailability of the each day Wegovy capsule with an efficacy and security that’s in line with what we see with the injectable formulation of Wegovy,” she says. “On the finish of the week, the common publicity ranges of the 2 formulations are constant.”
Wegovy capsule is just not the primary oral GLP-1 that Novo Nordisk has launched. Rybelsus is a semaglutide capsule that the FDA permitted in 2019 to deal with diabetes. Doustdar says that Rybelsus and the Wegovy capsule will differ in dose and within the circumstances they deal with. Wegogy capsule incorporates about double the best dose of Rybelsus, which is what research confirmed is important to realize a significant weight reduction.
Since each the injectable and capsule variations of Wegovy comprise the identical principal ingredient, semaglutide, the capsule’s label additionally notes it may possibly decrease the chance of coronary heart illness.
Wegovy capsule is the primary oral GLP-1 permitted by the FDA to deal with weight problems. On Dec. 18, Novo Nordisk’s competitor Eli Lilly submitted an FDA request for approval of its GLP-1 capsule, orforglipron, to assist individuals keep weight reduction after finishing a year-long collection of utilizing an injectable GLP-1. In November, Lilly acquired a Commissioner’s Precedence Voucher, which implies the assessment course of for the drug might be shortened from months to weeks.
Each Novo Nordisk and Eli Lilly joined with the White Home to make GLP-1 medicine, together with the tablets, extra inexpensive. The upkeep dose of the tablets will price $149 for a month’s provide for individuals who do not use insurance coverage or who acquire them by means of authorities packages.
Novo Nordisk plans to launch the Wegovy capsule in January.
